Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease
Introduction
Gastrointestinal dysfunction is a prominent non-motor feature of Parkinson's disease (PD). PD patients experience symptoms that span the entire alimentary tract including abnormal salivation, dysphagia, delayed gastric emptying, constipation, and defecatory dysfunction (Pfeiffer, 2003, Pfeiffer and Quigley, 1999). Dysfunctional motility is the pathophysiological mechanism underlying many of these symptoms. This dysmotility contributes directly to the morbidity of PD and complicates the disease's clinical management. For example, in the stomach, delayed emptying leads to nausea, contributes to weight loss because of decreased food intake, and adds to fluctuations in motor impairment from variable absorption of medication (Djaldetti et al., 1996, Goetze et al., 2006, Goetze et al., 2005, Kurlan et al., 1988). In the colon, longer transit time due to poor motility causes harder stools and constipation by increasing the absorption of water (Ashraf et al., 1995, Edwards et al., 1992, Ueki and Otsuka, 2004). The exact mechanism of motility dysfunction in PD is poorly understood. Lack of understanding of the changes in the gastrointestinal tract in PD has led to limited success in the treatment of gastrointestinal dysfunction in PD.
Control of gastrointestinal motility arises from both local and central locations. Local control is directed by the intrinsic enteric nervous system (ENS), a semiautonomous network of nerves that consists of a deep myenteric and more superficial submucosal plexus (Johnson, 2001). The myenteric plexus is the more important of the two in terms of controlling motility. Circuitry in this plexus controls the contraction and relaxation of the circular and longitudinal smooth muscle that line the length of the gastrointestinal tract. Though neurons producing virtually every neurotransmitter seen in the central nervous system have been identified within the ENS, acetylcholine serves as the primary excitatory neurotransmitter, while nitric oxide and vasoactive intestinal peptide are the prominent inhibitory transmitters (Johnson, 2001). Effective peristalsis depends on precise temporal coordination of inhibition and excitation of the two layers of smooth muscle. Central control arises from the autonomic inputs imposed on the local enteric nervous system. Parasympathetic, cholinergic innervation originates primarily in the dorsal motor nucleus of the vagus (DMV) in the medulla and generally promotes increased motility. Sympathetic input originates in paravertebral and sacral ganglia and generally serves to inhibit gastrointestinal motility.
Although PD has traditionally been considered a disease of dopaminergic neurons in the substantia nigra, pathological analyses of brain and gastrointestinal samples from PD patients have suggested neuronal loss in other areas. Lewy bodies have been described in both the myenteric and submucosal plexuses of the ENS (Braak et al., 2006, Kupsky et al., 1987, Singaram et al., 1995, Wakabayashi et al., 1988, Wakabayashi et al., 1989, Wakabayashi et al., 1990), and other research has found lower levels of enteric dopaminergic neurons in ENS of PD patients (Singaram et al., 1995). Central areas associated with gastrointestinal motility have also been implicated. For example, Braak et al. (2003) suggest that the DMV is perhaps the earliest central site affected in PD because α-synuclein pathology in the DMV was found in brains without damage to the substantia nigra (Braak et al., 2003).
One factor that has made research into the etiology of gastrointestinal dysfunction and evaluation of effective treatments difficult has been the absence of an animal model for this aspect of PD. The aim of the present research was to evaluate gastrointestinal dysfunction in a well-described animal model of PD using the selective dopamine neurotoxin MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine) (Jackson-Lewis et al., 1995). Animals treated with MPTP were behaviorally evaluated for signs of dysmotility in the stomach, small intestine, and colon. In addition, samples were examined for evidence of neuronal dysfunction and loss in the ENS. The results suggest that MPTP is a selective dopaminergic neurotoxin in the ENS and causes changes in colonic motility.
Section snippets
Animals and MPTP treatment
All experimental procedures were in accordance with the NIH Guide for the Care and Use of Experimental Animals and approved by the Emory University Institutional Animal Care and Use Committee. Male C57Bl/6 mice (6–8 months old) were administered MPTP in saline vehicle at a total dose of 60 mg/kg of MPTP given in four intraperitoneal injections 2 h apart on a single day (Teismann et al., 2003). Controls received saline using the same protocol. Following behavioral analysis, mice were
MPTP selectively damages catecholaminergic neurons in the ENS
When examined after 10 days, MPTP-treated animals had a greater than 40% reduction in the density of TH-positive neurons in the ENS (Fig. 1A). Due to the relatively low number of TH-positive enteric neurons, results are expressed as TH-positive neurons per ganglion to normalize for section area (Fig. 1B). Quantitative assessment of fiber density was not performed, but there were clearly TH-positive fibers remaining in the myenteric plexus. There were no significant differences in NADPH (nitric
Discussion
This is the first comprehensive description of gastrointestinal dysmotility in an animal model of Parkinson's disease. Parenteral administration of MPTP using a dosing paradigm that consistently causes dopaminergic neurodegeneration in the substantia nigra of mice concomitantly induces dopaminergic neurodegeneration in the enteric nervous system (ENS) that is associated with behavioral and electrophysiological consequences. The accelerated colon motility and colonic muscle relaxation defect
Acknowledgments
This work supported by NIH grants K08 NS048858 (JGG), KO8 DK067045 (SS), the Michael J. Fox Foundation for Parkinson's Research (JGG, SS), the Emory Digestive Diseases Research Center (DK064399), and a Cotzias Fellowship from the American Parkinson Disease Association (JGG).
References (39)
- et al.
Glial-derived neurotrophic factor modulates enteric neuronal survival and proliferation through neuropeptide Y
Gastroenterology
(2006) - et al.
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system
Neurobiol. Dis.
(2006) - et al.
Toxin-induced models of Parkinson's disease
NeuroRx
(2005) - et al.
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol. Aging
(2003) - et al.
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology
Neurosci. Lett.
(2006) - et al.
Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine
Biochem. Pharmacol.
(1988) - et al.
Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test
Neurosci. Lett.
(2005) - et al.
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neurodegeneration
(1995) - et al.
Effect of celiac ganglionectomy on tachykinin innervation, receptor distribution and intestinal responses in the rat
J. Auton. Nerv. Syst.
(1996) Gastrointestinal dysfunction in Parkinson's disease
Lancet Neurol.
(2003)
A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine
J. Physiol. (Paris)
Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation
Lancet
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease
Brain Res.
Effect of clonidine on colonic motility in rats
Auton. Neurosci.
Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease
Neuroscience
Frequency of bowel movements and the future risk of Parkinson's disease
Neurology
GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway
J. Clin. Invest.
Anorectal function in fluctuating (on–off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography
Mov. Disord.
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease
Isr. J. Med. Sci.
Cited by (196)
The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases
2022, Neuroscience and Biobehavioral ReviewsModeling dopamine dysfunction in autism spectrum disorder: From invertebrates to vertebrates
2022, Neuroscience and Biobehavioral ReviewsResearch progress in pathogenesis and treatment of gastrointestinal motility disorders in Parkinson’s disease
2024, Journal of Jilin University Medicine EditionCharacterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content
2024, European Journal of NeuroscienceExploring the nigrostriatal and digestive interplays in Parkinson’s disease using dynamic total-body [<sup>11</sup>C]CFT PET/CT
2024, European Journal of Nuclear Medicine and Molecular Imaging